JP2023524061A - 操作された中枢神経系用組成物 - Google Patents

操作された中枢神経系用組成物 Download PDF

Info

Publication number
JP2023524061A
JP2023524061A JP2022566315A JP2022566315A JP2023524061A JP 2023524061 A JP2023524061 A JP 2023524061A JP 2022566315 A JP2022566315 A JP 2022566315A JP 2022566315 A JP2022566315 A JP 2022566315A JP 2023524061 A JP2023524061 A JP 2023524061A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
mutation
protein
vector system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022566315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524061A5 (cg-RX-API-DMAC7.html
Inventor
パルディス サベッティ
ムハンマドシャリフ タブボードバー
サイモン イー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Broad Institute
Original Assignee
Massachusetts Institute of Technology
Broad Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology, Broad Institute filed Critical Massachusetts Institute of Technology
Publication of JP2023524061A publication Critical patent/JP2023524061A/ja
Publication of JP2023524061A5 publication Critical patent/JP2023524061A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022566315A 2020-05-01 2021-04-30 操作された中枢神経系用組成物 Withdrawn JP2023524061A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063019221P 2020-05-01 2020-05-01
US63/019,221 2020-05-01
US202063061517P 2020-08-05 2020-08-05
US63/061,517 2020-08-05
PCT/US2021/030298 WO2021222831A2 (en) 2020-05-01 2021-04-30 Engineered central nervous system compositions

Publications (2)

Publication Number Publication Date
JP2023524061A true JP2023524061A (ja) 2023-06-08
JP2023524061A5 JP2023524061A5 (cg-RX-API-DMAC7.html) 2024-05-13

Family

ID=78373993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022566315A Withdrawn JP2023524061A (ja) 2020-05-01 2021-04-30 操作された中枢神経系用組成物

Country Status (7)

Country Link
US (1) US20230193316A1 (cg-RX-API-DMAC7.html)
EP (1) EP4143305A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023524061A (cg-RX-API-DMAC7.html)
CN (1) CN115867646A (cg-RX-API-DMAC7.html)
AU (1) AU2021264061A1 (cg-RX-API-DMAC7.html)
CA (1) CA3176506A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021222831A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166208B (zh) 2018-10-02 2024-11-22 沃雅戈治疗公司 重新定向aav衣壳的嗜性
US12630842B2 (en) 2020-05-13 2026-05-19 Voyager Therapeutics, Inc. Redirection of tropism of AAV capsids
CA3210955A1 (en) * 2021-02-09 2022-08-18 Affinia Therapeutics Inc. Recombinant aavs with improved tropism and specificity
CA3216419A1 (en) * 2021-04-23 2022-10-27 Greg NACHTRAB Tissue-targeted modified aav capsids and methods of use thereof
WO2022226375A1 (en) * 2021-04-23 2022-10-27 Locanabio, Inc. Tissue-targeted modified aav capsids and methods of use thereof
KR20240095539A (ko) 2021-10-08 2024-06-25 디노 테라퓨틱스, 인코포레이티드 캡시드 변이체 및 이의 사용 방법
EP4426716A1 (en) 2021-11-02 2024-09-11 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2024046393A1 (zh) * 2022-08-30 2024-03-07 上海鲸奇生物科技有限公司 非神经元细胞转分化为神经元的方法及应用
AU2023364350A1 (en) 2022-10-19 2025-06-05 Affinia Therapeutics Inc. Recombinant aavs with improved tropism and specificity
JP2026509271A (ja) 2023-03-10 2026-03-17 ダイノ セラピューティクス,インコーポレーテッド カプシドポリペプチドおよびその使用方法
AU2024271851A1 (en) 2023-05-16 2025-12-18 Affinia Therapeutics Inc. Recombinant aavs with improved tropism and specificity
WO2025007046A1 (en) * 2023-06-29 2025-01-02 The Trustees Of The University Of Pennsylvania Mutant aav with central nervous system targeting motifs and compositions containing same
KR20260082361A (ko) 2023-08-31 2026-06-04 디노 테라퓨틱스, 인코포레이티드 캡시드 폴리펩타이드 및 이의 사용 방법
CN117165677A (zh) * 2023-11-03 2023-12-05 首都儿科研究所 检测生物标志物在制备神经管畸形疾病的产品的应用
WO2025160155A1 (en) 2024-01-22 2025-07-31 The Broad Institute, Inc. Epigenetic targeting of prion diseases
TW202545971A (zh) 2024-02-08 2025-12-01 美商戴諾治療公司 殼體多肽及其使用方法
WO2026064442A2 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2026122963A1 (en) 2024-12-06 2026-06-11 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160039877A1 (en) * 2013-03-15 2016-02-11 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
AU2015349759B2 (en) * 2014-11-21 2022-01-06 The University Of North Carolina At Chapel Hill Aav vectors targeted to the central nervous system
CA3172682A1 (en) * 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
AU2016366549B2 (en) * 2015-12-11 2022-11-10 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (AAVs)
AU2018350700B2 (en) * 2017-10-16 2025-04-24 VeonGen Therapeutics GmbH AAV vectors
IL278598B2 (en) * 2018-05-11 2025-11-01 Massachusetts Eye & Ear Infirmary Altering tissue tropism of adeno-associated viruses
EP3830107A2 (en) * 2018-08-03 2021-06-09 Voyager Therapeutics, Inc. Aav variants with enhanced tropism
CN113166208B (zh) * 2018-10-02 2024-11-22 沃雅戈治疗公司 重新定向aav衣壳的嗜性
WO2023039480A2 (en) * 2021-09-08 2023-03-16 The Broad Institute, Inc. Engineered central nervous system compositions

Also Published As

Publication number Publication date
AU2021264061A1 (en) 2022-12-01
EP4143305A2 (en) 2023-03-08
WO2021222831A2 (en) 2021-11-04
US20230193316A1 (en) 2023-06-22
EP4143305A4 (en) 2024-09-11
CA3176506A1 (en) 2021-11-04
CN115867646A (zh) 2023-03-28
WO2021222831A3 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
US20230193316A1 (en) Engineered central nervous system compositions
US12410447B2 (en) Engineered muscle targeting compositions
US20260071237A1 (en) Engineered adeno-associated virus capsids
US20240424143A1 (en) Engineered muscle and central nervous system compositions
US20250002541A1 (en) Engineered central nervous system compositions
CA3183530A1 (en) Engineered muscle targeting compositions
US12618082B2 (en) Engineered muscle targeting compositions
JP2025500347A (ja) 操作された心筋組成物
US20250090688A1 (en) Engineered muscle targeting compositions
US20250339554A1 (en) Compositions and methods for delivering cargo to a target cell
CA3148356A1 (en) Engineered adeno-associated virus capsids
US20240384299A1 (en) Targeting moieties promoting transduction of central nervous system cells and tissues and methods of use
WO2024006988A2 (en) Engineered delivery vesicles and uses thereof
US20220257677A1 (en) Engineered adeno-associated virus capsids
EA051488B1 (ru) Сконструированные нацеленные на мышцы композиции

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240430

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250425